Humacyte Research to Be Highlighted at AHA Scientific Sessions 2026
Humacyte founder and CEO Laura Niklason is scheduled to deliver an invited talk at the American Heart Association Scientific Sessions 2026.
Related stories
Nasdaq single-stock trading halt continues, symbol not given — reason not given (10:35 AM ET)
Nasdaq kept trading halted in a single listed security (reason not given) at 10:35 AM ET.
M impact | EQUITY | Nov 03, 2026, 03:52 PM UTC
CVR Energy Shares Fall After Equity Offering for Refinery Acquisition
CVR Energy shares declined after it launched an equity offering to fund its acquisition of a Marathon refinery.
L impact | EQUITY | Nov 03, 2026, 03:38 PM UTC
S&P 500 and Nasdaq Edge Higher Ahead of Midterm Results; Apple Falls 2%
US stocks rose as crude oil prices fell ahead of midterm election results. Apple shares dropped 2% after its earnings failed to impress investors.
M impact | EQUITY | Nov 03, 2026, 03:38 PM UTC
Pfizer lifts full-year guidance after robust third-quarter results
Pfizer reported third-quarter revenue of $16.6 billion, largely unchanged from a year earlier. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally.
M impact | EQUITY | Nov 03, 2026, 03:38 PM UTC
Meta Platforms Reportedly Targets Up to $25 Billion Bond Sale
Meta Platforms has reportedly launched an investment-grade bond sale, targeting up to $25 billion.
M impact | EQUITY | Nov 03, 2026, 03:37 PM UTC
Apollo Reports $53 Billion in Third-Quarter Inflows, AUM Reaches $1.07 Trillion
Apollo Global Management said demand for private credit, insurance and other alternative investments helped drive record fee-related earnings.
M impact | EQUITY | Nov 03, 2026, 03:36 PM UTC